Interim results from a study investigating OpRegen suggest a single treatment may provide improvements in patients with dry age-related macular degeneration with geographic atrophy, according to a Lineage Cell Therapeutics press release.
OpRegen, an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space, demonstrated positive findings in the phase 1/2a clinical study. In cohort 4, in which patients had better baseline vision and smaller geographic atrophy areas than previous cohorts, 67% of the treated eyes of 12